Introduction
Fetal hematopoietic stem cells (HSCs) proliferate rapidly and contribute to massive expansion of the HSC pool (1, 2) . In contrast, adult HSCs divide rarely in steady-state conditions, as a majority of cells reside in the quiescent G 0 phase of the cell cycle and return to quiescence after periods of proliferation (3) (4) (5) (6) (7) (8) . In mice, transition from the fetal/neonatal to the adult HSC program occurs in the bone marrow (BM) niche within weeks after birth and coincides with establishment of HSC quiescence, functional and phenotypic changes, and downregulated expression of the transcription factor Sox17 and other fetal HSC genes (1, (9) (10) (11) (12) . Failure to establish or maintain quiescence has been linked to adult HSC depletion, increased sensitivity to myeloablation, and reduced engraftment in transplantation assays (1, (13) (14) (15) (16) . However, the regulatory mechanisms controlling quiescence and successful initiation of the adult HSC program in the BM remain poorly understood.
The trithorax group (TrxG) is a diverse family of epigenetic regulators originally identified to control body patterning in Drosophila (17) . In flies, individual TrxG members cooperate to promote expression of homeobox (Hox) genes, and combined heterozygous TrxG gene mutations act as dominant enhancers of one another (18, 19) . Mixed-lineage leukemia 1 (Mll1) is the trithorax homolog and founding TrxG member in mammals. In humans, MLL1 was first identified as a recurrent translocation partner in acute leukemias characterized by upregulated HOX gene expression (20) (21) (22) (23) .
Endogenous Mll1 regulates expression of Hox genes and other targets as well as the function of normal HSCs (24) (25) (26) . Mll1 encodes a large protein containing a C-terminal Su(var)3-9/enhancer-ofzeste/trithorax (SET) domain with H3K4 histone methyltransferase activity (27) . MLL1 functions as a part of a multiprotein complex that includes RBBP5, WDR5, and ASH2L (28) (29) (30) (31) . Limited information is available about cooperative interactions among mammalian TrxG members, in particular with proteins in which an association with the MLL complex has not been as yet identified.
The TrxG gene absent, small, or homeotic 1 (ash1) was first discovered in genetic screens seeking regulators of Drosophila imaginal discs (32) . ash1 encodes a large protein containing an internal SET domain with putative histone methyltransferase activity (33) . Its mammalian homolog Ash1l also encodes a SET domain-containing protein that can associate with actively transcribed loci, including at several Hox genes (34) (35) (36) . However, unlike the much smaller protein ASH2L, ASH1L has not been identified so far as a member of the MLL protein complex. Recently, the ASH1L SET domain was reported to have intrinsic H3K36 dimethyltransferase activity using in vitro biochemical assays (37) (38) (39) . Neither the physiological significance of Ash1l nor the idea of cooperativity with Mll1 and other TrxG members has been evaluated in vivo.
In this report, we describe an essential role for the TrxG member Ash1l in the maintenance and function of adult HSCs but not in the in vivo expansion of fetal or neonatal hematopoietic progenitors. Ash1l was essential for the establishment of quiescence at the fetal to adult HSC transition in the BM within weeks after birth. Ash1l deficiency led to profound depletion of adult HSCs and multipotent progenitors as well as to a lack of functional HSCs capable of long-term BM reconstitution in transplantation assays. Unlike
Rapidly cycling fetal and neonatal hematopoietic stem cells (HSCs) generate a pool of quiescent adult HSCs after establishing hematopoiesis in the bone marrow. We report an essential role for the trithorax group gene absent, small, or homeotic 1-like (Ash1l) at this developmental transition. Emergence and expansion of Ash1l-deficient fetal/neonatal HSCs were preserved; however, in young adult animals, HSCs were profoundly depleted. Ash1l-deficient adult HSCs had markedly decreased quiescence and reduced cyclin-dependent kinase inhibitor 1b/c (Cdkn1b/1c) expression and failed to establish long-term trilineage bone marrow hematopoiesis after transplantation to irradiated recipients. Wild-type HSCs could efficiently engraft when transferred to unirradiated, Ash1l-deficient recipients, indicating increased availability of functional HSC niches in these mice. Ash1l deficiency also decreased expression of multiple Hox genes in hematopoietic progenitors. Ash1l cooperated functionally with mixed-lineage leukemia 1 (Mll1), as combined loss of Ash1l and Mll1, but not isolated Ash1l or Mll1 deficiency, induced overt hematopoietic failure. Our results uncover a trithorax group gene network that controls quiescence, niche occupancy, and self-renewal potential in adult HSCs.
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells taining a splice-acceptor cassette in the first Ash1l intron ( Figure  1A ). This strategy resulted in a >90% reduction of full-length Ash1l transcripts in fetal liver and BM lineage -SCA1 + c-KIT + (LSK) HSCs and hematopoietic progenitor cells. Ash1l was expressed in all subpopulations of LSK progenitors and in selected mature cell subsets ( Figure 1B) . Homozygosity for the Ash1l GT allele preserved fetal liver and BM cellularity as well as myeloid, erythroid, and B lineage cells in Ash1l GT/GT mice compared with that in Ashl +/+ littermates ( Figure 1, C and D) . The capacity to form myeloid colonies was normal in Ash1l-deficient BM, consistent with preserved progenitor numbers and function ( Figure 1E ).
We quantified HSCs as the CD150 + CD48 -fraction of LSK progenitors, a definition that identifies both fetal and adult long-term HSCs (LT-HSCs) (40, 41) . Ash1l-deficient LT-HSCs were present at normal frequency in the fetal liver, showing that phenotypically defined fetal LT-HSCs emerged and expanded normally in these mice (Figure 2A ). HSC numbers were also preserved in the in wild-type recipients, after nonmyeloablative transplantation of normal HSCs, cells could efficiently engraft the BM and establish durable hematopoiesis in Ash1l-deficient mice, suggesting poor competition of residual HSCs for niche space. Despite profound defects in transplantation assays, Ash1l-deficient mice exhibited no overt hematopoietic failure in steady-state conditions, with evidence of increased self-renewal in progenitors downstream of HSCs. However, combining Ash1l deficiency with inactivation of the TrxG gene Mll1 or its cofactor gene Men1 led to rapid BM failure. These data reveal an essential physiological function for the TrxG gene Ash1l in adult HSCs and represent the first genetic demonstration of cooperativity between TrxG members in mammals.
Results

Ash1l-deficient mice have normal numbers of fetal and neonatal HSCs but profound depletion of adult HSCs.
To examine the function of Ash1l in hematopoiesis, we used a gene trap insertion allele con- GT/GT mice (n = 4 mice per genotype from 2 experiments; mean ± SEM). (D) Complete blood counts of 24-week-old mice, showing reduced platelets but preserved lymphocytes, neutrophils, and hemoglobin contents (n = 6 mice per genotype; mean ± SEM). (E) BM cellularity and progenitor contents in 24-week-old mice (n = 6 mice per genotype from 3 experiments; mean ± SEM) and 48-week-old mice (n = 3 per genotype from 2 experiments; mean ± SEM). Flow cytometric analysis demonstrates a reduction in LSK progenitors and persistent 5-to 10-fold reduction in LT-HSCs. *P < 0.05, **P < 0.01, ***P < 0.001, t test. pattern of activity was preserved with Ash1l-deficient progenitors at early time points after transplantation, with the bulk of short-term reconstitution coming from the CD48 -LSK fraction (2-4 weeks after transplant). As observed with transplantation of total BM, however, phenotypically defined MPP/LT-HSCs were functionally unable to sustain long-term reconstitution. These data suggest that Ash1l-deficient CD48 -LSK cells can home to the BM and provide initial progeny but lack long-term self-renewal potential.
We next examined Ash1l GT/GT LT-HSC function after transplantation without competition. The majority of irradiated Ash1l
GT/GT BM recipients died within 10 to 150 days after transplantation, consistent with transient radioprotection but suggestive of LT-HSC dysfunction ( Figure 3E ). Surviving Ash1l GT/GT BM recipients exhibited host CD45.1 + reconstitution and no Ash1l GT/GT LT-HSCs ( Figure 3F ). Thus, Ash1l
GT/GT BM did not house transplantable LT-HSCs, even as defined by noncompetitive transplantation.
We then performed transplantation using fetal liver as the donor source, thereby normalizing phenotypic LT-HSC frequency and eliminating the possibility that stromal BM defects contributed to LT-HSC dysfunction ( Figure 4A ). Ash1l
GT/GT fetal liver progenitors were incapable of sustaining myeloid, B, and T lineage reconstitution after transplantation ( Figure 4B ). Analysis of the BM at 17 to 26 weeks after transplantation showed no detectable Ash1l
GT/GT LT-HSCs ( Figure 4C ). Thus, fetal Ash1l GT/GT LT-HSCs were present in normal numbers, as defined phenotypically, but could not establish durable hematopoiesis in the BM after transplantation, indicating that they were functionally defective once transferred into the postnatal environment.
To evaluate the homing capacity of Ash1l-deficient progenitors, we analyzed recipient BM 24 hours after transplantation into nonirradiated mice (Supplemental Figure 4A ). Equivalent numbers of donor-derived wild-type and Ash1l
GT/GT cells were recovered (Supplemental Figure 4B ). Similar observations were made in irradiated recipients (data not shown). Altogether, our findings reveal profound LT-HSC dysfunction that becomes apparent in the context of the adult BM niche after transplantation, despite preserved initial homing and even when fetal cells are used as a source of progenitors.
The Ash1l-deficient BM supports wild-type HSC engraftment in the absence of myeloablation. Since Ash1l GT/GT BM had reduced LT-HSCs that were nonfunctional in transplantation assays, we reasoned that available niche space and/or defective progenitors could allow engraftment of donor HSCs without myeloablation. We infused 2 boluses of wild-type CD45.1
GT/GT mice without prior irradiation ( Figure 5A ). Few, if any, donor-derived cells engrafted in wild-type recipients, as expected. In contrast, the majority (7 of 8) of Ash1l GT/GT recipients achieved stable or steadily rising trilineage output from infused BM, as shown by the 20% to 90% donor-derived contribution to blood lineages for ≥12 weeks ( Figure 5B ). At completion of the experiment, donor LT-HSCs were present in the Ash1l GT/GT BM ( Figure 5C ). Thus, the Ash1l GT/GT BM niche supported long-term stable engraftment by wild-type HSCs, while residual Ash1l GT/GT HSCs and hematopoietic progenitor cells competed poorly for niche space.
Neonatal Ash1l GT/GT HSCs home to the BM but fail to establish a quiescent adult HSC pool. As LT-HSC loss was first observed in young adult Ash1l
GT/GT BM, we studied BM HSCs within 1 to 3 weeks after neonatal liver (data not shown). However, by 6 to 12 weeks after birth, LT-HSCs had decreased by 5-to 10-fold in Ash1l GT/GT BM as compared with BM of wild-type littermates ( Figure 2B ). A similar profound reduction was observed using the CD34 GT/GT mice (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI78124DS1). Despite persistent LT-HSC depletion, 24-week-old Ash1l-deficient mice maintained normal blood counts, except for modest thrombocytopenia ( Figure 2D ). Overall BM cellularity remained preserved at 24 weeks as well as at 48 weeks of life. Flow cytometric analysis showed persistent profound LT-HSC depletion, while numbers of LSK progenitors were reduced only by about 30% at 24 weeks and 50% at 48 weeks ( Figure 2E ). These data suggest a specific role of Ash1l in the maintenance of adult BM HSCs, with downstream compensatory mechanisms preserving overall hematopoietic function in steady-state conditions.
To evaluate whether the hematopoietic phenotype of Ash1l-deficient mice was associated with mobilization of BM HSCs and hematopoietic progenitor cells into the periphery, we assessed LSK and LT-HSC frequency as well as colony-forming activity in the spleen (Supplemental Figure 2) . The frequency of spleen LSK/LTHSCs and granulocyte-macrophage CFU (CFU-GM) colonies was decreased in Ash1l GT/GT mice. These findings indicate the absence of a mobilization phenotype in these mice and suggest that the maintenance of adult Ash1l-deficient hematopoietic progenitors was relatively more impaired outside as compared with that within the BM.
Ash1l-deficient mice lack HSCs capable of long-term BM reconstitution after transplantation. As the gold standard definition of LT-HSCs is based on their function (45, 46) , we studied the long-term reconstitution potential of Ash1l-deficient progenitors in transplantation assays ( Figure 3A ). This strategy allowed us to evaluate LT-HSC function irrespective of surface phenotype. We transplanted lethally irradiated CD45. GT/GT BM failed to support long-term trilineage reconstitution of the myeloid, B, and T cell compartments ( Figure 3B ). Analysis of BM LT-HSCs 10-16 weeks after transplantation showed a complete absence of Ash1l GT/GT LT-HSCs ( Figure 3 , C and D). The lack of significant reconstitution beyond a few weeks was consistent with the depletion of both LT-HSCs and multipotent progenitors in Ash1l-deficient mice, as defined using CD150/CD48 expression (43) . To examine the relative contribution of CD48 reported (12) , but absent in both wild-type and Ash1l GT/GT adult HSCs ( Figure 6C ). Thus, Ash1l deficiency did not result in the maintenance of a global fetal HSC state.
We next assessed cell cycle status in Ash1l GT/GT HSCs. As shown by Ki67/DAPI staining, P19 Ash1l GT/GT HSCs had a markedly reduced G 0 fraction, increased entry into G 1 , and a trend for more HSCs in S/G 2 /M phases of the cell cycle ( Figure 6D ). Since most HSCs exit the cell cycle in the BM between P14 and P21 (1), this suggested that Ash1l-deficient HSCs failed to establish a quiescent stem cell pool at the fetal to adult transition. P19 Ash1l GT/GT LT-HSCs but not total BM or c-KIT hi SCA1
hi cells also showed increased BrdU incorporation (Supplemental Figure 5) . Recent work showed that BM HSC birth. At this stage, Ash1l GT/GT mice had a normal frequency of phenotypically defined LT-HSCs in the BM, indicating preserved initial homing from the liver ( Figure 6 , A and B, and data not shown). However, P19 Ash1l GT/GT HSCs showed increased expression of CD34 ( Figure 6B ). In mice, CD34 is upregulated in cycling HSCs and marks fetal but not the most quiescent adult mouse LT-HSCs (3, 10) . To test whether Ash1l GT/GT BM HSCs aberrantly maintained a fetal program, we used a Sox17-GFP reporter to study expression of Sox17, a master regulator of fetal HSCs (11) . Ash1l GT/GT HSCs were Sox17-GFP + in the fetal liver and extinguished Sox17 expression by 2 weeks after birth ( Figure 6C) . A similar pattern was observed for Lin28b transcripts, which were detected in fetal HSCs, as previously quiescence is dependent on combined effects of the cyclin-dependent kinase inhibitors p27 (encoded by Cdkn1b) and p57 (encoded by Cdkn1c) (15, 47) . Ash1l GT/GT BM LSK cells had markedly decreased expression of these two critical regulators ( Figure 6E ). Expression of p21 (encoded by Cdkn1a) was not altered. These data suggest that Ash1l directly or indirectly regulates p27 and p57 expression during establishment of quiescence in young adult HSCs.
We next challenged Ash1l GT/GT and control mice with 5-fluorouracil (5-FU) ( Figure 7A ). 5-FU treatment is toxic to dividing cells but spares quiescent cells, including many normal LT-HSCs. A single 5-FU treatment resulted in a 2-log reduction of Ash1l GT/GT LT-HSCs compared with controls, thereby worsening LT-HSC loss in Ash1l GT/GT mice by 10-to 20-fold ( Figure 7B ). This was consistent with increased sensitivity of Ash1l GT/GT HSCs to 5-FU, due, at least in part, to decreased quiescence. Consistent with these findings, 5-FU administration was associated with impaired survival of Ash1l-deficient mice, even after administration of a single dose (Figure 7, C and D) .
Increased cumulative proliferation of hematopoietic progenitors compensates for HSC loss in Ash1l-deficient mice. HSC loss and profound defects in transplantation assays contrasted with preservation of hematopoietic output under steady-state conditions in Ash1l-deficient mice. To explore this paradox, we used a pulsechase H2B-GFP-labeling system to study proliferation history of phenotypically defined HSCs as well as downstream progenitors that normally have limited self-renewal potential ( Figure 8A  and ref. 8 ). This strategy allows tetracycline-induced expression of H2B-GFP in all cells (pulse), followed by dilution of GFP fluorescence upon cell division after tetracycline withdrawal (chase).
Ash1l
GT/GT LT-HSCs had increased proliferation throughout the 6-week chase period, as indicated by enhanced GFP dilution (Figure 8B) . The entire Ash1l
GT/GT LSK compartment had markedly increased proliferation as compared with control LSK cells. We could not detect a residual population of LSK or Lin -cells with high GFP fluorescence in Ash1l-deficient mice, consistent with the absence of highly quiescent progenitors ( Figure 8B ). In contrast, we observed a markedly increased proportion of Ash1l GT/GT Lin -GFP -cells that had preserved a primitive LSK phenotype after 6 weeks of chase ( Figure 8C ). These findings suggest that increased selfrenewal of progenitors downstream of HSCs could compensate for LT-HSC loss and sustain hematopoietic output in Ash1l GT/GT mice. GT/GT n = 10 mice, ***P < 0.001, t test; horizontal bars show the mean). jci.org Volume 125
Number 5 May 2015
Ash1l regulates the expression of multiple Hox genes. In flies, TrxG members collaborate to maintain Hox gene expression during development. We reasoned that, if mammalian TrxG members cooperated with one another, they might also share target genes and functional effects. Mll1, the mammalian homolog of fly trithorax, regulates expression of multiple Hoxa genes and Hox-related genes, such as Meis1. Ash1l
GT/GT LSK progenitors had reduced expression of Hoxa3, Hoxa4, Hoxa5, Hoxa6, Hoxa9, Hoxa10, and Meis1 ( Figure 9 ). Thus, Ash1l and Mll1 might share multiple target genes, including Hox genes (25, (48) (49) (50) Mx1-Cre + mice, using a conditional Mll1 allele reported to induce only mild hematopoietic defects upon inactivation in steady-state conditions (26) . This strategy allowed deletion of one or both Mll1 alleles via poly(I:C) injection in the presence of graded Ash1l doses ( Figure 10A ). Combined Mll1 and Ash1l deficiency resulted in rapid and profound reduction in BM cellularity, suggesting hematopoietic failure (Figure 10B) . Figure 10C ). CD34 -LT-HSCs, a highly quiescent adult HSC subset identified with surface markers in mice, were particularly sensitive to inactivation of an increasing number of Ash1l and Mll1 alleles ( Figure 10D ), suggesting that Ash1l and Mll1 cooperate to maintain quiescent HSCs. However, multipotent progenitors and overall BM cellularity were only depleted upon targeting of both Mll1 and Ash1l alleles (Figure 10, B-D) . Finally, we assessed the combined effects of Ash1l deficiency and inactivation of Men1, encoding the MLL1 cofactor menin (Supplemental Figure 6) . Menin is essential for recruitment of the MLL1 complex, at least to a subset of target genes, and was previously shown to regulate HSC homeostasis (53) (54) (55) . Profound thrombocytopenia, BM hypocellularity, and loss of all hematopoietic progenitors were observed upon combined deficiency of both Ash1l and Men1 alleles but not when even one of the four alleles was maintained (Supplemental Figure 6, B-D) . LT-HSCs were particularly sensitive to graded loss of Ash1l and Men1 alleles. (Supplemental Figure 6D) . Although only some Mll1 target genes are sensitive to Men1 loss (50), these genes may be important for the cooperative effects of Ash1l and Mll1 in hematopoiesis. Together, these findings reveal cooperativity between Ash1l and Mll1 or Men1 in HSCs and hematopoietic progenitor cells, uncovering a unique sensitivity of quiescent adult HSCs to regulation by the TrxG family.
Discussion
Our findings uncover an essential function for the TrxG gene Ash1l in the regulation of adult HSCs and reveal functional cooperativity of TrxG members in hematopoiesis. When Ash1l levels were GT/GT BM failed to achieve long-term reconstitution in irradiated recipients after competitive and noncomprofoundly reduced in Ash1l GT/GT mice, the ability of young adult LT-HSCs to establish and maintain quiescence was impaired. Ash1l-deficient HSCs developed and expanded normally in the fetal liver and initially seeded the BM. Once in the BM, these LT-HSCs did not upregulate expression of Cdkn1b/c, which was associated with reduced numbers of quiescent HSCs. Because fetal HSCs are known to divide rapidly, these results could have arisen from the persistence of a fetal program upon reaching the BM. However, expression of Sox17 and Lin28b, two essential regulators of the fetal HSC transcriptional program, was properly extinguished in BM Ash1l
GT/GT LT-HSCs, indicating that their GT/GT LSK progenitors (qRT-PCR, n = 3 per group, mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001, t test. jci.org Volume 125 Number 5 May 2015
Ash1l-deficient mice did not progress to frank hematopoietic failure, despite severe depletion of phenotypically defined LTHSCs and lack of transplantable HSCs. A possible explanation for these findings is that few residual LT-HSCs could maintain steady-state hematopoiesis through a compensatory increase in proliferation. Using H2B-GFP in a pulse-chase system (8), we indeed observed increased cumulative proliferation of all primitive Ash1l GT/GT hematopoietic progenitors, consistent with the absence of a slowly cycling progenitor pool. A striking feature of Ash1l-deficient hematopoiesis, however, was the large increase in cells that maintained a primitive LSK phenotype, despite the complete loss of GFP at the end of the chase period. Thus, Ash1l-deficient progenitors downstream of LT-HSCs showed evidence of increased self-renewal in vivo in the absence of a normal HSC compartment. This phenomenon is reminiscent of recent observations that early thymocyte progenitors acquire extended self-renewal in vivo when the normal input of blood-derived T lineage progenitors is impaired, suggesting that self-renewal potential can be modulated in individual hematopoietic progenitors as an adaptation to pathological conditions (60, 61) . It is interesting to speculate about why compensatory changes in Ash1l-deficient mice were not sustained after transplantation into irradiated recipients. Emerging evidence indicates that steady-state hematopoiesis and stress hematopoiesis after transplantation are regulated by different mechanisms (62) . After transplantation, hematopoiesis is driven by a small number of LT-HSCs that outcompete other progenitors, while steadystate hematopoiesis can be maintained for extended periods of time by a broader range of downstream progenitors with more petitive transplantation. Based on this gold standard approach of HSC biology, we could not detect LT-HSC function in the Ash1l GT/GT BM, indicating that the presence of functional HSCs with an alternative phenotype was unlikely. Furthermore, we could also not detect functional LT-HSCs after transplantation of Ash1l GT/GT fetal liver progenitors, which had LT-HSC frequency comparable to that of Ash1l +/+ mice by phenotypic criteria. Thus, despite their normal in vivo expansion in the fetal/neonatal liver, Ash1l
GT/GT LT-HSCs could not establish durable hematopoiesis in the BM niche after transplantation, indicating that they were functionally abnormal, even if they expanded normally in the fetal environment. As normal numbers of Ash1l
GT/GT
HSCs were initially present in the neonatal BM, our data are consistent with preserved HSC homing to the BM in these mice but also with failure to respond to niche factors that are required for the establishment of quiescence and subsequent stable engraftment. Among putative essential niche-derived factors in the BM, thrombopoietin (TPO) and TGF-β have been linked to induction of quiescence through Cdkn1b/c upregulation (14, 56, 57) . Furthermore, decreased expression of multiple posterior Hoxa genes was observed in young adult HSCs of TPO-deficient mice (14) . Thus, Ash1l may be necessary to establish a normal transcriptional response downstream of TPO or other essential BM niche factors required for adult HSC quiescence, maintenance, and function. As genetic inactivation of Hoxa9 and other Hoxa genes was shown to cause HSC defects, we speculate that decreased expression of multiple Hoxa genes accounts for part of the defects in Ash1l-deficient HSCs, although other factors are likely involved as well (58, 59). poorly for niche space. Either scenario is consistent with extreme LT-HSC dysfunction when Ash1l levels are reduced. Of note, the full effects of Ash1l could be even more profound than observed in Ash1l GT/GT mice, as these mice had low residual levels of normal Ash1l transcripts, consistent with Ash1l
GT being a severely hypomorphic but not a null allele.
Cooperative effects of Mll1 and Ash1l in hematopoiesis highlight an evolutionarily conserved feature of TrxG members, a phenomenon identified in flies but not previously described in mammals. Loss of a single Ash1l
GT allele amplified LT-HSC depletion in Men1-deficient and Mll1-deficient mice, while complete restricted potential. Thus, it is possible that Ash1l-deficient mice were competent for this type of hematopoiesis but selectively deficient in LT-HSC function after transplant.
Only a few genetic models of HSC dysfunction that support nonablative transplantation have been reported in hematopoietic biology (52, 63) . In Ash1l GT/GT mice, successful engraftment in nonablative transplantation experiments suggested that the Ash1l-deficient BM niche was not defective, as it could support maintenance of wild-type LT-HSCs. Stable wild-type LT-HSC engraftment suggested that niche spaces were available due to LT-HSC depletion and/or that remaining Ash1l
GT/GT LT-HSCs competed Flow cytometry. Single cell suspensions were prepared from fetal liver, BM, or blood, followed by red blood cell lysis (ACK buffer, Cambrex). The following antibodies were from BioLegend: anti-CD3, anti-CD4, anti-CD8, anti-CD11b, anti-CD11c, anti-CD19, anti-CD48, anti-CD150, anti-Gr1/Ly-6G, anti-B220, anti-NK1.1, anti-TCRβ, anti-TCRγδ, and anti-cKIT. Anti-SCA1 was from eBiosciences. We used the following antibody cocktail to exclude lineage + cells: anti-CD11b, anti-Gr1, anti-CD11c, anti-B220, anti-CD19, anti-CD3, anti-TCRβ, anti-TCRγδ, anti-CD8, anti-NK1.1, and anti-Ter119. In fetal samples, CD11b was omitted. BrdU analysis was performed using a BrdU Labeling Kit (BD Biosciences). Ki67 staining was achieved using the BD Ki67 Set (BD Biosciences). Analysis was performed on a FACSCanto and sorting was performed on a FACSAria II/III (BD Biosciences). Dead cells were excluded with 4′6-diamidino-2-phenylindole (Sigma-Aldrich). Flow cytometry files were analyzed with FlowJo (TreeStar).
BM and fetal liver cell transplantation. Six-to eight-week-old B6-SJL (CD45.1 + ) mice were lethally irradiated (900 Gy, 37 Cs source). Four hours after irradiation, mice were transplanted with 6-to 10-week-old donor BM or E15. 5 Complete blood counts. Blood was obtained through retroorbital bleeding and transferred to EDTA-treated tubes. Complete blood counts were determined using the Advia 120 Hematology System (Siemens).
CFU-GM. 20,000 BM cells or 200,000 spleen cells were plated per ml of MethoCult GF M3534 (Stem Cell Technologies). Colonies were scored 7 to 10 days later.
Quantitative real-time PCR. For gene expression analyses, at least 5,000 cells from each population of interest were sort purified directly into Trizol (Invitrogen). After RNA extraction, cDNA was generated using the SuperScript III First-Strand Synthesis Kit (Invitrogen) or the Nugen hematopoietic failure was observed only when all 4 alleles were deficient. This dominant phenotypic enhancement is reminiscent of criteria used to identify TrxG members in Drosophila. To date, the biochemical mechanisms underlying this genetic observation remain poorly understood. Given that both Mll1 and Ash1l are required for Hox gene expression, it is possible that MLL1 and ASH1L proteins act nonredundantly to promote transcription at a shared subset of target genes. Indeed, both Ash1l
GT/GT and Mll1-or Men1-deficient hematopoietic progenitors displayed a reduced, but not absent, expression of posterior Hoxa genes, suggesting multifactorial regulation at this locus (25, 50, 54) . Since MLL1 and ASH1L SET domains have H3K4 and H3K36 methyltransferase activity, two histone marks that are involved in transcription initiation and elongation steps, respectively, it can be envisioned that they target different regulatory steps of transcription. In this scenario, either Mll1 or Ash1l inactivation can lead to compromised Hoxa gene expression. It also remains to be determined whether the cooperative interaction between Mll1 and Ash1l is limited to the regulation of Hoxa genes in LT-HSCs, especially since Mll1 was reported to control multiple other genes in normal hematopoiesis (50) . Future work should explore the detailed molecular mechanisms by which TrxG members cooperatively regulate quiescent adult HSCs.
Methods
Mice. C57BL/6.Ptprca (B6-SJL, CD45.1 + ) mice were from the National Cancer Institute. B6-GFP transgenic mice expressing GFP under the control of the human ubiquitin C promoter were from The Jackson Laboratory (64 Mx1-Cre + mice (8, 11, 26, 65, 66) . To label hematopoietic cells with H2B-GFP, Rosa26-rtTA TetOP-H2B-GFP mice were maintained on doxycycline (2 mg/ml in drinking water) for 6 weeks. Mice were -LT-HSC numbers in 2 hind legs, showing high sensitivity of this population to regulation by TrxG members. *P < 0.05, **P < 0.01, ***P < 0.001, compared with wild type; # P < 0.05, ## P < 0.01, compared with Ash1l GT/GT ; † P < 0.05, † † P < 0.01, † † † P < 0.001, compared with induced Mll fl/fl Mx1-Cre + , t test.
